IPS cells: A game changer for future medicine

EMBO Journal

Volumn 33, Issue 5, 2014, Pages 409-417

  Inoue, Haruhisa ^a,b   Nagata, Naoki ^a   Kurokawa, Hiromi ^a   Yamanaka, Shinya ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

cell transplantation; cohort study; disease modeling; future medicine; iPSC clinical trial; patient stratification

Indexed keywords

ALPHA TOCOPHEROL; BETA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR; VALPROIC ACID;

ALZHEIMER DISEASE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG RESPONSE; ENRICHMENT CULTURE; GENE EXPRESSION; HUMAN; MODEL; MOLECULAR DIAGNOSIS; NONHUMAN; NUCLEAR REPROGRAMMING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; TOXICITY TESTING;

CLINICAL TRIALS AS TOPIC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MEDICINE; MODELS, THEORETICAL; STEM CELL TRANSPLANTATION;

EID: 84898608302     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1002/embj.201387098     Document Type: Review

References (65)

1. Auffray C, Chen Z, Hood L, (2009) Systems medicine: the future of medical genomics and healthcare. Genome Med 1: 2
2. Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J, Park IH, Friedman BA, Daley GQ, Wyllie DJ, Hardingham GE, Wilmut I, Finkbeiner S, Maniatis T, Shaw CE, Chandran S, (2012) Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci USA 109: 5803-5808
3. Citri A, Pang ZP, Südhof TC, Wernig M, Malenka RC, (2012) Comprehensive qPCR profiling of gene expression in single neuronal cells. Nat Protoc 7: 118-127
4. Deshmukh RS, Kovács KA, Dinnyés A, (2012) Drug discovery models and toxicity testing using embryonic and induced pluripotent stem-cell-derived cardiac and neuronal cells. Stem Cells Int 2012: 379569
5. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K, (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321: 1218-1221
6. Egashira T, Yuasa S, Fukuda K, (2013) Novel insights into disease modeling using induced pluripotent stem cells. Biol Pharm Bull 36: 182-188
7. Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, et al, (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4: 145ra104.
8. Garbes L, Heesen L, Hölker I, Bauer T, Schreml J, Zimmermann K, Thoenes M, Walter M, Dimos J, Peitz M, Brüstle O, Heller R, Wirth B, (2013) VPA response in SMA is suppressed by the fatty acid translocase CD36. Hum Mol Genet 22: 398-407
9. Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL, (2011) Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 123: 281-289
10. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R, (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920-1923
11. Hester ME, Murtha MJ, Song S, Rao M, Miranda CJ, Meyer K, Tian J, Boulting G, Schaffer DV, Zhu MX, Pfaff SL, Gage FH, Kaspar BK, (2011) Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol Ther 19: 1905-1912
12. Hiramatsu K, Sasagawa S, Outani H, Nakagawa K, Yoshikawa H, Tsumaki N, (2011) Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors. J Clin Invest 121: 640-657
13. Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, Hu Y, Wang X, Hui L, (2011) Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475: 386-389
14. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D, (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142: 375-386
15. Imamura K, Inoue H, (2012) Research on neurodegenerative diseases using induced pluripotent stem cells. Psychogeriatrics 12: 115-119
16. Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T, Wada R, Katsumata Y, Kaneda R, Nakade K, Kurihara C, Obata Y, Miyake K, Fukuda K, Ieda M, (2012) Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ Res 111: 1147-1156
17. Inamura M, Kawabata K, Takayama K, Tashiro K, Sakurai F, Katayama K, Toyoda M, Akutsu H, Miyagawa Y, Okita H, Kiyokawa N, Umezawa A, Hayakawa T, Furue MK, Mizuguchi H, (2011) Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX. Mol Ther 19: 400-407
18. Inoue H, Yamanaka S, (2011) The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 89: 655-661
19. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS, (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482: 216-220
20. Jin ZB, Okamoto S, Osakada F, Homma K, Assawachananont J, Hirami Y, Iwata T, Takahashi M, (2011) Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS ONE 6: e17084
21. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, et al, (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99
22. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S, Puri PL, Leone TC, Marine JE, Calkins H, Kelly DP, Judge DP, Chen HS, (2013) Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494: 105-110
23. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, et al, (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467: 285-290
24. Kitaoka S, Kondoh H, Inoue H, (2011) Induced pluripotent stem cell technology for the study of neurodegenerative diseases. In Induced Stem Cells, Sullivan PJ, Mortensen EK, (eds), pp 129-142. New York: Nova Science Publishers Inc
25. Kobayashi T, Yamaguchi T, Hamanaka S, Kato-Itoh M, Yamazaki Y, Ibata M, Sato H, Lee YS, Usui J, Knisely AS, Hirabayashi M, Nakauchi H, (2010) Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 142: 787-799
26. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, et al, (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12: 487-496
27. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkelä E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setälä K, (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5: 220-230
28. Marchetto MC, Gage FH, (2012) Modeling brain disease in a dish: really? Cell Stem Cell 10: 642-645
29. Medine CN, Lucendo-Villarin B, Storck C, Wang F, Szkolnicka D, Khan F, Pernagallo S, Black JR, Marriage HM, Ross JA, Bradley M, Iredale JP, Flint O, Hay DC, (2013) Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med 2: 505-509
30. Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K, (2012) Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 10: 595-609
31. Merkle FT, Eggan K, (2013) Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 12: 656-668
32. Mirnezami R, Nicholson J, Darzi A, (2012) Preparing for precision medicine. N Engl J Med 366: 489-491
33. Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahashi J, (2013) Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Reports 1: 283-292
34. Nakajima F, Tokunaga K, Nakatsuji N, (2007) Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 25: 983-985 (Pubitemid 46572595)
35. Nakaki F, Hayashi K, Ohta H, Kurimoto K, Yabuta Y, Saitou M, (2013) Induction of mouse germ-cell fate by transcription factors in vitro. Nature 501: 222-226
36. Nakamura M, Okano H, (2013) Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res 23: 70-80
37. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, et al, (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12: 114-126
38. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S, (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8: 409-412
39. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ, (2008) Disease-specific induced pluripotent stem cells. Cell 134: 877-886
40. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, Srivastava D, (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485: 593-598
41. Qiang L, Fujita R, Abeliovich A, (2013) Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron 78: 957-969
42. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, Aubry L, Vanti WB, Moreno H, Abeliovich A, (2011) Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 146: 359-371
43. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A, (2013) Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. Nature 500: 45-50
44. Sandoe J, Eggan K, (2013) Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 16: 780-789
45. Sasai Y, (2013) Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. Cell Stem Cell 12: 520-530
46. Scott CW, Peters MF, Dragan YP, (2013) Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 219: 49-58
47. Sekiya S, Suzuki A, (2011) Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475: 390-393
48. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lõpez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, et al, (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512
49. Soldner F, Jaenisch R, (2012) Medicine. iPSC disease modeling. Science 338: 1155-1156
50. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, Woolf CJ, Eggan K, (2011) Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9: 205-218
51. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, Olson EN, (2012) Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485: 599-604
52. Szabo E, Rampalli S, Risueño RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-Martin M, Bhatia M, (2010) Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468: 521-526
53. Takahashi K, Yamanaka S, (2013) Induced pluripotent stem cells in medicine and biology. Development 140: 2457-2461
54. Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A, Manabe Y, Fujii N, Hanaoka K, Era T, Yamashita S, Isobe K, Kimura E, Sakurai H, (2013) Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One 8: e61540
55. Tobert (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors Nat Rev Drug Discov. 2: 517-526
56. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M, (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463: 1035-1041
57. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, Koseki H, Kawamoto H, (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12: 31-36
58. Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, Tanaka T, Yasutomi Y, Yamada T, Minakami H, Tanaka J, Oda A, Sasaki T, Wakao R, Lantz O, Udagawa T, Sekiya Y, Higuchi K, Harada N, Nishimura K, et al, (2013) Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12: 546-558
59. Winklhofer KF, Tatzelt J, Haass C, (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27: 336-349 (Pubitemid 351161650)
60. Xu XH, Zhong Z, (2013) Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin 34: 755-764
61. Yamanaka S, (2012) Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10: 678-684
62. Yu DX, Marchetto MC, Gage FH, (2013) Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 12: 678-688
63. Zerhouni EA, (2005) US biomedical research: basic, translational, and clinical sciences. JAMA 294: 1352-1358 (Pubitemid 41345814)
64. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, Xu W, Yang N, Danko T, Chen L, Wernig M, Südhof TC, (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78: 785-798
65. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA, (2008) In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455: 627-632